TLR7 and systemic lupus erythematosus: While the initial studies are encouraging, more research is needed to fully evaluate the safety of NANP-mediated TLR7 activation because a recent study provided the first causation link between TLR7 activation and systemic lupus erythematosus (SLE), an autoimmune disorder (106), which is in line with the earlier clinical observation of TLR7-agonist association with psoriasis, an autoinflammatory skin disorder (107).